NHS to roll out ‘transformational’ glucose monitors for people with type 1 diabetes

By Editor
3rd August 2022
Continuous glucose monitoring, Latest news NHS Type 1 diabetes

Individuals with type 1 diabetes are now eligible for “life-changing” continuous glucose monitors after the NHS has secured a new cut-price deal.

The wearable arm gadget sends information to a mobile app and allows people with type 1 diabetes to keep track of their glucose levels without having to scan or take a finger prick test.

Continuous glucose monitors are normally more expensive than their flash monitor counterparts – which record glucose levels by scanning a sensor – but thanks to the NHS agreeing on a new cost-effective deal with manufacturers Dexcom, they will now be available for people on prescription at a similar price.

The monitor, called Dexcom ONE rt-CGM, uses a sensor no bigger than a bottle cap that attaches to the arm for up to 10 days and measures glucose levels from just under the skin.

People will receive their starter pack – which will include information on the product and usage, a sensor and transmitter – from the hospital or GP surgery once prescribed, after which they can go to the pharmacy for their repeat prescription.

In April, GlucoRx was the first company to roll out free continuous glucose monitors (CGMs) to people with type 1 diabetes on the NHS  with 14 days use. The GlucoRx AiDEX CGM has been available on the Drug tariff since April 1, 2022.

The Dexcom deal comes after the NHS surpassed its initial Long Term Plan target to ensure 20 per cent of people with type 1 diabetes were benefiting from flash monitors by March 2021 ahead of schedule – with recent data showing nearly three-fifths are already accessing the technology.

The wider rollout of the technology will help people with diabetes manage their condition better – reducing hospitalisations and associated diabetic illnesses which will ultimately ease pressure off the NHS.

Dr Partha Kar, national speciality advisor for diabetes and obesity said: “This is a huge step forward for type 1 diabetes care and these monitors will be life-changing for anyone with the illness – giving them more choice to manage their condition in the most convenient way possible – as well as the best chance at living healthier lives, reducing their risk of hospitalisation and illnesses associated with diabetes, which in turn reduces pressure on wider NHS services.

“The new deal also delivers on our commitment to get people the latest cutting-edge medical technology at the best value for taxpayer money – saving the NHS millions over the coming years.”

Former Prime Minister Theresa May said: “This is another important step for the NHS in treating people with type 1 diabetes.

“CGM makes a huge difference to people living with diabetes – it is truly transformational. I am pleased that the NHS has already surpassed the target in the Long Term Plan for the number of people benefiting from flash monitoring. There is more to do but these are huge steps forward”.

Health Minister James Morris said: “This is an excellent example of how technology can help people manage their long-term conditions from the comfort of their own homes, reducing pressure on the NHS and improving health outcomes.

“We’re determined to harness the latest technology to improve healthcare across the country. Thanks to the NHS for negotiating this great deal which delivers value for money and benefits patients.”

Karen Baxter, Vice President, UK & Ireland, Benelux, France and Spain at Dexcom: “The addition of Dexcom ONE to the NHS England drug tariff is enormous progress towards improving the choice of diabetes tech, providing an alternative to burdensome finger pricks and scanning.

“We are incredibly proud of the diabetes community and are working hard to make it easier for them to access the best technology possible to manage their diabetes.”

She added: “As a next step, we will be working closely with healthcare professionals to ensure the diabetes community can benefit as quickly as possible from reimbursement and the wider availability of Dexcom CGM.”

The NHS spends approximately £10 billion a year on treating diabetes, with the Type 2 Diabetes Prevention Programme aiming to combat thousands of people from developing the illness and free up NHS resources in the long term.

A multitude of other diabetes technologies have also been made available on the NHS such as the Freestyle Libre.

Comments (1)

  1. Richard Page says:

    How about Type 2 diabetics? Why are we treated as second rate sufferers? We too need to control our sugar levels and to do that we need to know what things increase sugar levels.

    We need to know the impact of exercise, of drinking water, of sleep, of the different foods we eat. If we are unable to do this consistently then our sugar levels will fluctuate wildly and will cause damage to our bodies and resulting morbidities such as:

    • Eye problems (retinopathy)
    • Foot problems
    • Heart attack and stroke
    • Kidney problems (nephropathy)
    • Nerve damage (neuropathy)
    • Gum disease and other mouth problems
    • Related conditions, like cancer
    • Sexual problems in women
    • Sexual problems in men

    The only reason Type 1 diabetics get monitors is because they have an immediate risk of a hypo. Apart from that the mid to long term co-morbidities are very much the same.

    So why can we not be prescribed these monitors or at the minimum get the sensors at an NHS subsidised rate.

    Hell anything that reduces the cost of subsequent treatments such as amputations etc. is a great preventative and cost saving exercise over the long term.

    Time for the Diabetes Times to support our cause and fight the corner for Type 2 diabetics as well. It’s not right or equitable to treat diabetics differently because they are essentially the same disease when it comes to the health complications.